Online Access Free RAPS.RAC-US.v2025-10-02.q35 Practice Test (Page 4)

RAC-US Exam Question 11

You discover that your company's top selling product in the last two years has been used off-label.
The off-label use is estimated to be about 70%, and it has been consistent since the product was first released to the market. Which of the following is MOST appropriate?

A.Advise the senior management to send a "Dear Dr." letter.

B.No action is required since it is an off-label use.

C.Discuss with regulatory authorities to investigate how to have the off-label indication approved.

D.File a report to regulatory authorities and advise the marketing department to prevent future off-label use.

RAC-US Exam Question 12

Which of the following is the MOST desirable timing and approach for a regulatory affairs professional who wants to provide feedback on proposed new regulations?

A.After the enactment of the regulation, through a product-specific meeting

B.Before the enactment of the regulation, through the industry representative

C.After the enactment of the regulation, through the industry representative

D.Before the enactment of the regulation, through formal comments gathering process

RAC-US Exam Question 13

At the last internal audit, a regulatory affairs professional identified a need for a corrective action for the manufacturing process. Which of the following stakeholders should be notified FIRST?

A.Clinical affairs

B.Quality improvement

C.Regulatory agency

D.Quality assurance

RAC-US Exam Question 14

Which of the following is an example of an acceptable statement for an advertisement of an approved arthritis medication?

A."Product X is a guaranteed cure for arthritis."

B."Product X is effective for the treatment of arthritis."

C."Product X is safe for arthritis and without side effects."

D."Product X is effective in all patients with arthritis."

RAC-US Exam Question 15

Which of the following BEST describes the content of the "Physical, Chemical, and
Pharmaceutical Properties and Formulation" section of an IB?

A.A detailed summary of the physical and chemical properties of the drug product with a signed expert statement addressing the suitability and stability of the formulation for its intended use

B.A description and flow chart illustrating the synthetic route for the active ingredient and the preparation method of the finished product

C.A review of available data to support the determination of the chemical structure and physical attributes of the drug substance plus batch analysis and stability data for the finished formulation

D.A brief summary of relevant physical, chemical, and pharmaceutical properties:
instructions for storage and handling of the dosage form: and a description of the formulation

Other Version: 1459RAPS.RAC-US.v2025-01-09.q36; 1403RAPS.RAC-US.v2024-06-21.q35; 117RAPS.Practicematerial.RAC-US.v2022-05-19.by.marvin.36q.pdf; 2565RAPS.RAC-US.v2022-03-19.q36; 2788RAPS.RAC-US.v2022-03-04.q34; 118RAPS.Examboosts.RAC-US.v2021-08-19.by.gustave.28q.pdf

Latest Upload: 143CrowdStrike.CCSE-204.v2026-06-12.q25; 163VMware.2V0-17.25.v2026-06-12.q49; 154Appian.ACA-100.v2026-06-11.q23; 210CompTIA.220-1202.v2026-06-11.q114; 164CheckPoint.156-590.v2026-06-11.q47; 225CompTIA.220-1202.v2026-06-10.q109; 209CertiProf.CEHPC.v2026-06-10.q54; 152Hitachi.HQT-4160.v2026-06-10.q25; 405PMI.PMI-ACP-CN.v2026-06-09.q453; 193Splunk.SPLK-5002.v2026-06-08.q52

RAC-US Exam Question 11

RAC-US Exam Question 12

RAC-US Exam Question 13

RAC-US Exam Question 14

RAC-US Exam Question 15

Download PDF File